|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
9 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expense | |||||
| Loss from operations | |||||
| OTHER INCOME (EXPENSES), NET | |||||
| Interest expense – related party | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Interest expense | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Series B convertible preferred stock financing costs – related party | |||||
| Change in fair value of debt, other liabilities, and derivatives – related party | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Change in fair value of debt, other liabilities, and derivatives | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Change in fair value of other liabilities and derivatives | |||||
| Change in fair value of other liabilities and derivatives – related party | |||||
| Grant income | |||||
| Debt extinguishment | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Gain on sale of investment in Nova Cell | |||||
| Other income, net | |||||
| Total other income (expenses), net | |||||
| LOSS BEFORE INCOME TAXES | |||||
| Income tax provision | |||||
| NET LOSS | |||||
| Net loss attributable to noncontrolling interest | |||||
| NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST | |||||
| Deemed dividend on warrants | |||||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | |||||
| Net loss per share, basic | |||||
| Total net loss per share, basic | |||||
| Net loss per share, diluted | |||||
| Total net loss per share, diluted | |||||
| Weighted average common shares outstanding, basic | |||||
| Total weighted average common shares outstanding, basic | |||||
| Weighted average common shares outstanding, diluted | |||||
| Total weighted average common shares outstanding, diluted | |||||
Loading...